MCID: CTN007
MIFTS: 66

Cutaneous Leishmaniasis

Categories: Infectious diseases

Aliases & Classifications for Cutaneous Leishmaniasis

MalaCards integrated aliases for Cutaneous Leishmaniasis:

Name: Cutaneous Leishmaniasis 37 12 14
Asian Desert Cutaneous Leishmaniasis 12 69
Diffuse Cutaneous Leishmaniasis 12 69
Leishmaniasis, Cutaneous 41 69
Ethiopian Cutaneous Leishmaniasis 69
Leishmaniasis Diffuse Cutaneous 51
Leishmaniasis Cutaneous 51
Leproid Leishmaniasis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9111
ICD10 32 B55.1
MeSH 41 D016773
NCIt 46 C34768
SNOMED-CT 64 240637006

Summaries for Cutaneous Leishmaniasis

Disease Ontology : 12 A leishmaniasis that involves skin infection caused by Leishmania species, resulting in one or more cutaneous lesions.

MalaCards based summary : Cutaneous Leishmaniasis, also known as asian desert cutaneous leishmaniasis, is related to acquired immunodeficiency syndrome and african tick-bite fever. An important gene associated with Cutaneous Leishmaniasis is IFNG (Interferon Gamma), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Miconazole and Miltefosine have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are hematopoietic system and digestive/alimentary

Related Diseases for Cutaneous Leishmaniasis

Diseases related to Cutaneous Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
# Related Disease Score Top Affiliating Genes
1 acquired immunodeficiency syndrome 30.3 IFNG IL10 TNF
2 african tick-bite fever 30.2 IFNG IL13
3 lepromatous leprosy 29.8 IFNG IL10 TLR2 TNF
4 leprosy 3 29.7 IFNG IL10 IL4 SLC11A1 TLR2 TNF
5 folliculitis 29.5 IFNG IL4 IL5
6 dermatitis 29.5 IFNG IL13 IL4 IL5
7 melioidosis 29.4 IFNG IL10 TLR2 TLR4 TNF
8 leishmaniasis 29.4 IFNG IL10 IL13 IL4 IL5 LMLN
9 trypanosomiasis 29.0 IFNG IL10 IL4 TLR2 TLR9 TNF
10 visceral leishmaniasis 29.0 FOXP3 IFNG IL10 IL13 IL4 LMLN
11 pulmonary tuberculosis 28.7 IFNG IL10 IL4 SLC11A1 TLR2 TLR9
12 mycobacterium tuberculosis 1 28.3 IFNG IL10 IL4 SLC11A1 TLR2 TLR4
13 mucocutaneous leishmaniasis 11.7
14 kala-azar 1 11.5
15 mycoplasmal pneumonia 10.6 IFNG IL4
16 punctate inner choroidopathy 10.6 IL10 TNF
17 staphylococcal toxic shock syndrome 10.5 IFNG TNF
18 autoimmune myocarditis 10.5 IFNG TNF
19 microscopic polyangiitis 10.5 IL10 TNF
20 multifocal choroiditis 10.5 IL10 TNF
21 ascaridiasis 10.5 IL10 IL13
22 immunoglobulin a deficiency 1 10.5 IL10 IL4
23 persistent polyclonal b-cell lymphocytosis 10.5 FCER2 IL4
24 b-cell growth factor 10.5 IFNG IL4
25 hyperlucent lung 10.5 IFNG IL10 IL4
26 transient hypogammaglobulinemia 10.5 IL10 TNF
27 baylisascariasis 10.5 IFNG IL10 IL4
28 tropical endomyocardial fibrosis 10.5 IL10 IL4 TNF
29 clonorchiasis 10.5 IFNG IL10 TNF
30 variola major 10.5 IFNG TLR4
31 tungiasis 10.5 IL10 IL4 TNF
32 endomyocardial fibrosis 10.5 IL10 IL4 TNF
33 chronic beryllium disease 10.5 IFNG TNF
34 intermediate uveitis 10.4 IFNG IL10 TNF
35 microscopic colitis 10.4 IFNG IL4 TNF
36 neurosyphilis 10.4 IL10 TLR2
37 hemorrhagic fever 10.4 IFNG IL10 TNF
38 aseptic meningitis 10.4 IFNG IL10 TNF
39 spotted fever 10.4 IFNG IL10 TNF
40 hematopoietic stem cell transplantation 10.4 IFNG IL10 TNF
41 cytomegalovirus infection 10.4 IFNG IL10 TNF
42 plasmodium vivax malaria 10.4 IFNG IL10 TNF
43 penicillin allergy 10.4 IFNG IL13 IL4
44 trichosporonosis 10.4 IFNG TNF
45 mixed connective tissue disease 10.4 IFNG IL10 TNF
46 reactive arthritis 10.4 IFNG IL10 TNF
47 rasmussen encephalitis 10.4 IFNG IL4 TNF
48 aphthous stomatitis 10.4 IL10 IL4 TNF
49 sporotrichosis 10.4 IFNG IL10
50 dengue hemorrhagic fever 10.4 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Cutaneous Leishmaniasis:



Diseases related to Cutaneous Leishmaniasis

Symptoms & Phenotypes for Cutaneous Leishmaniasis

MGI Mouse Phenotypes related to Cutaneous Leishmaniasis:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 GPI IFNG FCER2 FOXP3 IL10 SLC11A1
2 digestive/alimentary MP:0005381 10.3 IL13 IFNG FCER2 FOXP3 IL10 SLC11A1
3 cellular MP:0005384 10.28 IL10 IFNG FCER2 FOXP3 IL13 MPI
4 immune system MP:0005387 10.27 GPI IFNG FCER2 FOXP3 IL10 SLC11A1
5 homeostasis/metabolism MP:0005376 10.26 IL10 GPI FCER2 IFNG FOXP3 IL13
6 growth/size/body region MP:0005378 10.25 IL10 GPI IFNG FOXP3 IL13 MPI
7 mortality/aging MP:0010768 10.18 IL10 GPI IFNG FCER2 FOXP3 MPI
8 liver/biliary system MP:0005370 10.06 IL10 GPI IFNG FOXP3 IL4 TLR2
9 integument MP:0010771 10.03 FOXP3 IL10 IFNG IL13 IL4 TLR2
10 neoplasm MP:0002006 9.87 IL10 IFNG SLC11A1 TLR2 IL5 TLR4
11 no phenotypic analysis MP:0003012 9.8 FOXP3 IL10 GPI IFNG IL13 IL4
12 reproductive system MP:0005389 9.76 FOXP3 IL10 IFNG IL5 IL13 IL4
13 respiratory system MP:0005388 9.65 GPI IL13 IFNG FOXP3 IL10 IL4
14 skeleton MP:0005390 9.28 IL10 IFNG IL13 MPI PGD IL4

Drugs & Therapeutics for Cutaneous Leishmaniasis

Drugs for Cutaneous Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2 58066-85-6 3600
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
4 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 meglumine antimoniate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anthelmintics Phase 4,Phase 2
10 Antimony Sodium Gluconate Phase 4,Phase 2
11 Anesthetics Phase 4
12
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
13
Paromomycin Approved, Investigational Phase 3,Phase 2,Early Phase 1 7542-37-2, 1263-89-4 165580
14
Imiquimod Approved, Investigational Phase 3,Phase 2 99011-02-6 57469
15
Aluminum sulfate Approved Phase 2, Phase 3, Phase 1 10043-01-3
16
Nitric Oxide Approved Phase 3 10102-43-9 145068
17
Pentamidine Approved, Investigational Phase 2, Phase 3 100-33-4 4735
18
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
19
Azithromycin Approved Phase 2, Phase 3 83905-01-5 53477736 447043 55185
20 Antioxidants Phase 2, Phase 3
21 Phosphodiesterase Inhibitors Phase 2, Phase 3
22 Platelet Aggregation Inhibitors Phase 2, Phase 3
23 Protective Agents Phase 2, Phase 3
24 Radiation-Protective Agents Phase 2, Phase 3
25 Vasodilator Agents Phase 2, Phase 3
26 Adjuvants, Immunologic Phase 2, Phase 3, Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antibiotics, Antitubercular Phase 3,Phase 2
29 Gentamicins Phase 3,Phase 2
30 Interferon Inducers Phase 3,Phase 2
31 interferons Phase 3,Phase 2
32 Vaccines Phase 2, Phase 3, Phase 1
33 Anti-Asthmatic Agents Phase 3
34 Autonomic Agents Phase 3
35 Bronchodilator Agents Phase 3
36 Endothelium-Dependent Relaxing Factors Phase 3
37 Neurotransmitter Agents Phase 3,Phase 2
38 Peripheral Nervous System Agents Phase 3
39 Respiratory System Agents Phase 3
40 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 3
42 Hormone Antagonists Phase 3
43 Hormones Phase 3
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
45 Steroid Synthesis Inhibitors Phase 3
46
Amphotericin B Approved, Investigational Phase 1, Phase 2 1397-89-3 5280965 14956
47
Allopurinol Approved Phase 2 315-30-0 2094
48 Molgramostim Investigational Phase 2 99283-10-0
49 Methyl 5-aminolevulinate Phase 2
50 Liposomal amphotericin B Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 74)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
2 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4 Meglumine antimoniate
3 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4 Miltefosine
4 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
5 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
6 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
7 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
8 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
9 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
10 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3 Imiquimod
11 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
12 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
13 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
14 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
15 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
16 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
17 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Recruiting NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
18 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Active, not recruiting NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
19 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
20 Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan Not yet recruiting NCT03208543 Phase 3
21 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
22 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
23 Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
24 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
25 Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
26 Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis Completed NCT02919605 Phase 2 Single dose of Pentacarinat®;Two doses of Pentacarinat®;Three doses of Pentacarinat®
27 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World Completed NCT00703924 Phase 2 WR 279,396;Placebo
28 WR 279,396 for the Treatment of Cutaneous Leishmaniasis Completed NCT01988909 Phase 2 WR 279,396
29 Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia Completed NCT01845727 Phase 1, Phase 2 Topical Amphotericin B at 3%
30 Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil) Completed NCT00600548 Phase 2 Miltefosine.;Meglumine antimoniate.;Miltefosine.;Meglumine antimoniate.
31 Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis Completed NCT00973128 Phase 2 GMCSF plus Antimony reduced dose;Meglumine antimoniate
32 Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis Completed NCT01380314 Phase 2 Miltefosine + Imiquimod;Miltefosine 150 mg x day + Placebo
33 Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Completed NCT00233545 Phase 2 miltefosine;antimony
34 Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis Completed NCT00884377 Phase 2 Sodium stibogluconate (Pentostam)
35 A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis Completed NCT01011309 Phase 2 Sodium stibogluconate
36 Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Completed NCT03294161 Phase 2 Immucillin DI4G;Meglumine antimoniate
37 A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis Completed NCT01536795 Phase 2 WR279 396 with Tegaderm Dressing;WR 279, 396 with Gauze and Tape Dressing
38 Intralesional Antimony for Bolivian Cutaneous Leishmaniasis Completed NCT01300975 Phase 2 pentavalent antimony;placebo cream
39 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01083576 Phase 2 WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream);Paromomycin Alone Cream (15% paromomycin topical cream)
40 Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) Completed NCT01032382 Phase 2 WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream);Paromomycin Alone Cream (15% paromomycin topical cream)
41 Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients Completed NCT00996463 Phase 2 Sodium Stibogluconate;DAC N-055
42 Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Completed NCT00004755 Phase 2 allopurinol;glucantime
43 Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396 Completed NCT00657917 Phase 2 Paromomycin +Gentamicin topical cream
44 Miltefosine Plus IL Pentamidine for Bolivian CL Completed NCT03445897 Phase 2 miltefosine plus intralesional pentamidine
45 Miltefosine to Treat Mucocutaneous Leishmaniasis Completed NCT01050907 Phase 2 miltefosine
46 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen Completed NCT00633009 Phase 2
47 Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite Completed NCT00121862 Phase 2
48 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
49 Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Recruiting NCT02687971 Phase 2 Miltefosine
50 Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis Not yet recruiting NCT02656797 Phase 2 Topical Amphotericin-B 0.4% liposomal gel

Search NIH Clinical Center for Cutaneous Leishmaniasis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: leishmaniasis, cutaneous

Genetic Tests for Cutaneous Leishmaniasis

Anatomical Context for Cutaneous Leishmaniasis

MalaCards organs/tissues related to Cutaneous Leishmaniasis:

38
Skin, Testes, T Cells, Monocytes, Neutrophil, Placenta, Breast

Publications for Cutaneous Leishmaniasis

Articles related to Cutaneous Leishmaniasis:

(show top 50) (show all 782)
# Title Authors Year
1
Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran. ( 29415078 )
2018
2
Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl. ( 29424815 )
2018
3
Climate and environmental factors affecting the incidence of cutaneous leishmaniasis in Isfahan, Iran. ( 29427273 )
2018
4
First case report of atypical disseminated cutaneous leishmaniasis in an opium abuser in Iran. ( 29451599 )
2018
5
Health economic evaluation of moist wound care in chronic cutaneous leishmaniasis ulcers in Afghanistan. ( 29444705 )
2018
6
Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia. ( 29378537 )
2018
7
Tissue Impression Smears as a Supplementary Diagnostic Method for Histopathology in Cutaneous Leishmaniasis in Sri Lanka. ( 29345220 )
2018
8
Leishmania (Viannia) braziliensis isolated from the saliva of patients in a cutaneous leishmaniasis-endemic area of northeastern Brazil. ( 29412341 )
2018
9
Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. ( 29329311 )
2018
10
Leishmania major cutaneous leishmaniasis outbreak in the Jordanian side of the Northern Jordan Valley. ( 29392995 )
2018
11
Cutaneous Leishmaniasis in the Metropolitan City of Multan, Pakistan, a Neglected Tropical Disease. ( 29415246 )
2018
12
Arnica Tincture Cures Cutaneous Leishmaniasis in Golden Hamsters. ( 29329207 )
2018
13
Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ Transplant Recipients and Donors. ( 29381573 )
2018
14
Isolation of Crithidia spp. from lesions of immunocompetent patients with suspected cutaneous leishmaniasis in Iran. ( 29446852 )
2018
15
The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. ( 28043177 )
2017
16
Analysis of expression of FLI1 and MMP1 in American cutaneous leishmaniasis caused by Leishmania braziliensis infection. ( 28119029 )
2017
17
Leishmania tropica: Combined debulking and imiquimod for the treatment of nonresponsive cutaneous leishmaniasis. ( 27986151 )
2017
18
Phlebotomines in an area endemic for American cutaneous leishmaniasis in northeastern coast of Brazil. ( 28902258 )
2017
19
Effect of secondary infection on epithelialisation and total healing of cutaneous leishmaniasis lesions. ( 28902290 )
2017
20
Effects of Bone Marrow Mesenchymal Stromal Cell Therapy in Experimental Cutaneous Leishmaniasis in BALB/c Mice Induced by Leishmania amazonensis. ( 28848541 )
2017
21
A Case of Cutaneous Leishmaniasis guyanensis Mimicking Otitis Externa. ( 28811000 )
2017
22
Leech therapy in treatment of cutaneous leishmaniasis: a case report. ( 28844218 )
2017
23
An Anti-Inflammatory Role for NLRP10 in Murine Cutaneous Leishmaniasis. ( 28931602 )
2017
24
An outbreak of cutaneous leishmaniasis in Modena province (Northern Italy): report of 35 cases. ( 29449723 )
2017
25
Spatial distribution, Leishmania species and clinical traits of Cutaneous Leishmaniasis cases in the Colombian army. ( 28850603 )
2017
26
Histopathologic features of cutaneous leishmaniasis and use of CD1a staining for amastigotes in Old World and New World leishmaniasis. ( 28892183 )
2017
27
Reprint of "Spatial modeling of Cutaneous Leishmaniasis in Iran from 1983 to 2013". ( 27914666 )
2017
28
Screening of TNFI+, IL-10 and TLR4 single nucleotide polymorphisms in individuals with asymptomatic and chronic cutaneous leishmaniasis in Colombia: a pilot study. ( 28241747 )
2017
29
A case report of co-infection of Melioidosis and cutaneous Leishmaniasis. ( 28764662 )
2017
30
In Vitro Immunomodulatory Activity of a Transition-State Analog Inhibitor of Human Purine Nucleoside Phosphorylase in Cutaneous Leishmaniasis. ( 28929123 )
2017
31
Cutaneous leishmaniasis in Algeria: quadrennial assessment (2008-2011). ( 28947409 )
2017
32
First description of Leishmania (Viannia) infection in Evandromyia saulensis, Pressatia sp. and Trichophoromyia auraensis (Psychodidae: Phlebotominae) in a transmission area of cutaneous leishmaniasis in Acre state, Amazon Basin, Brazil. ( 28076470 )
2017
33
Assessing the insecticide susceptibility status of field population of Phlebotomus papatasi (Diptera: Psychodidae) in a hyperendemic area of zoonotic cutaneous leishmaniasis in Esfahan Province, Central Iran. ( 28870534 )
2017
34
Detection and identification of cutaneous leishmaniasis isolates by culture, Polymerase chain reaction and sequence analyses in Syrian and Central Anatolia patients. ( 28889158 )
2017
35
Cutaneous leishmaniasis in a severely immunocompromised HIV patient in Kumbo, Northwest region of Cameroon: case report. ( 28841834 )
2017
36
The PCR-RFLP-Based Detection and Identification of the<i>Leishmania</i>Species Causing Human Cutaneous Leishmaniasis in the Khorasan-Razavi Province, Northeast of Iran. ( 29322055 )
2017
37
In Vitro and In Vivo Evaluation of Essential Oil from Artemisia absinthium L. Formulated in Nanocochleates against Cutaneous Leishmaniasis. ( 28930253 )
2017
38
An overview of skin lesions adapted to Cutaneous Leishmaniasis in Persian Medicine. ( 29403630 )
2017
39
Considerations of potential vectors and animal reservoirs in an emerging cutaneous leishmaniasis area in SALo Domingos ranch, ParanA! State in Southearn Brazil. ( 28876416 )
2017
40
Epidemiological Study on Cutaneous Leishmaniasis in an Endemic Area, of Qom Province, Central Iran. ( 29322057 )
2017
41
Dermatoscopic signs in cutaneous leishmaniasis. ( 29364445 )
2017
42
SLC11A1 polymorphisms and host susceptibility to cutaneous leishmaniasis in Pakistan. ( 28061874 )
2017
43
Rearing and Biology of<i>Phlebotomus sergenti</i>, the Main Vector of Anthroponotic Cutaneous Leishmaniasis in Iran. ( 29367927 )
2017
44
Aspects on the Ecology of Phlebotomine Sand Flies (Diptera: Psychodidae) From GuaraA-, State of Tocantins, Brazil, Endemic Area for American Cutaneous Leishmaniasis. ( 28082651 )
2017
45
Spatiotemporal and molecular epidemiology of cutaneous leishmaniasis in Libya. ( 28880944 )
2017
46
Modeling zoonotic cutaneous leishmaniasis incidence in central Tunisia from 2009-2015: Forecasting models using climate variables as predictors. ( 28841642 )
2017
47
Spatial distribution of cutaneous leishmaniasis in the state of ParanA!, Brazil. ( 28938013 )
2017
48
First report on molecular characterization of Leishmania species from cutaneous leishmaniasis patients in southern Khyber Pakhtunkhwa province of Pakistan. ( 28870350 )
2017
49
The new situation of cutaneous leishmaniasis after Syrian civil war in Gaziantep city, Southeastern region of Turkey. ( 27983970 )
2017
50
Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. ( 28926630 )
2017

Variations for Cutaneous Leishmaniasis

Expression for Cutaneous Leishmaniasis

LifeMap Discovery
Genes differentially expressed in tissues of Cutaneous Leishmaniasis patients vs. healthy controls: 35 (show top 50) (show all 174)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL9 chemokine (C-X-C motif) ligand 9 Skin + 6.42 0.000
2 CXCL10 chemokine (C-X-C motif) ligand 10 Skin + 6.16 0.000
3 IDO1 indoleamine 2,3-dioxygenase 1 Skin + 5.97 0.000
4 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) Skin + 5.88 0.000
5 GBP5 guanylate binding protein 5 Skin + 5.82 0.000
6 PIP prolactin-induced protein Skin - 5.80 0.000
7 GNLY granulysin Skin + 5.77 0.000
8 MMP1 matrix metallopeptidase 1 Skin + 5.47 0.000
9 DCD dermcidin Skin - 5.36 0.000
10 GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) Skin + 5.30 0.000
11 SCGB1D2 secretoglobin, family 1D, member 2 Skin - 5.14 0.000
12 CCL8 chemokine (C-C motif) ligand 8 Skin + 5.01 0.000
13 NKG7 natural killer cell granule protein 7 Skin + 4.99 0.000
14 GZMK granzyme K (granzyme 3; tryptase II) Skin + 4.89 0.000
15 SCGB2A2 secretoglobin, family 2A, member 2 Skin - 4.87 0.000
16 IGLL1 immunoglobulin lambda-like polypeptide 1 Skin + 4.82 0.000
17 CCL5 chemokine (C-C motif) ligand 5 Skin + 4.78 0.000
18 MMP3 matrix metallopeptidase 3 Skin + 4.69 0.000
19 CCL3L3 chemokine (C-C motif) ligand 3-like 3 Skin + 4.67 0.000
20 UBD ubiquitin D Skin + 4.67 0.000
21 ADAMDEC1 ADAM-like, decysin 1 Skin + 4.65 0.000
22 EPSTI1 epithelial stromal interaction 1 (breast) Skin + 4.53 0.000
23 JCHAIN joining chain of multimeric IgA and IgM Skin + 4.53 0.000
24 C5orf46 chromosome 5 open reading frame 46 Skin - 4.53 0.000
25 C1QB complement component 1, q subcomponent, B chain Skin + 4.51 0.000
26 GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) Skin + 4.48 0.000
27 GBP1 guanylate binding protein 1, interferon-inducible Skin + 4.45 0.000
28 CCL4L1 chemokine (C-C motif) ligand 4-like 1 Skin + 4.44 0.000
29 MED27 mediator complex subunit 27 Skin - 4.31 0.000
30 FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide Skin + 4.29 0.000
31 KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 Skin + 4.27 0.000
32 SERPINA12 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12 Skin - 4.25 0.000
33 GBP4 guanylate binding protein 4 Skin + 4.23 0.000
34 CD8A CD8a molecule Skin + 4.23 0.000
35 TDO2 tryptophan 2,3-dioxygenase Skin + 4.19 0.000
36 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) Skin + 4.17 0.000
37 CXCL8 chemokine (C-X-C motif) ligand 8 Skin + 4.13 0.000
38 KRT27 keratin 27, type I Skin - 4.13 0.000
39 DAPL1 death associated protein-like 1 Skin - 4.10 0.000
40 LYZ lysozyme Skin + 4.10 0.000
41 THRSP thyroid hormone responsive Skin - 4.06 0.000
42 CHP2 calcineurin-like EF-hand protein 2 Skin - 4.03 0.000
43 PRF1 perforin 1 (pore forming protein) Skin + 4.03 0.000
44 LAG3 lymphocyte-activation gene 3 Skin + 3.99 0.000
45 CYBB cytochrome b-245, beta polypeptide Skin + 3.98 0.000
46 WARS tryptophanyl-tRNA synthetase Skin + 3.98 0.000
47 CD3D CD3d molecule, delta (CD3-TCR complex) Skin + 3.97 0.000
48 IL18BP interleukin 18 binding protein Skin + 3.96 0.000
49 SNX10 sorting nexin 10 Skin + 3.96 0.000
50 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 Skin + 3.95 0.000
Search GEO for disease gene expression data for Cutaneous Leishmaniasis.

Pathways for Cutaneous Leishmaniasis

Pathways related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 FCER2 GPI IFNG IL10 IL13 IL4
2
Show member pathways
13.65 FCER2 IFNG IL10 IL13 IL4 IL5
3
Show member pathways
13.44 IL10 IL13 IL4 IL5 TLR2 TLR4
4
Show member pathways
13.36 FCER2 IFNG IL10 IL13 IL4 IL5
5
Show member pathways
13.23 FCER2 IFNG IL4 TLR2 TLR4 TLR9
6
Show member pathways
12.91 FOXP3 IFNG IL10 IL13 IL4 IL5
7
Show member pathways
12.85 IFNG IL13 IL4 TLR2 TLR4 TLR9
8
Show member pathways
12.6 IFNG IL10 TLR2 TLR4 TLR9 TNF
9 12.58 FOXP3 IFNG IL10 IL4 TLR2 TLR9
10
Show member pathways
12.55 IL13 IL4 IL5 TNF
11
Show member pathways
12.49 IFNG IL10 IL4 IL5 TNF
12
Show member pathways
12.44 IFNG IL10 IL13 IL4 IL5
13
Show member pathways
12.39 IFNG IL13 IL4 IL5 TLR2 TNF
14
Show member pathways
12.35 FOXP3 IFNG IL10 IL13 IL4 IL5
15
Show member pathways
12.31 IFNG IL10 IL4 TLR2 TLR4 TNF
16
Show member pathways
12.28 TLR2 TLR4 TLR9 TNF
17 12.27 IFNG IL10 TLR2 TLR4 TLR9 TNF
18 12.26 IFNG TLR2 TLR4 TLR9 TNF
19
Show member pathways
12.2 IFNG IL4 TLR2 TLR4 TLR9 TNF
20
Show member pathways
12.18 IFNG IL10 IL13 IL4 IL5 TNF
21
Show member pathways
12.11 IL13 IL5 TLR2 TLR4 TLR9
22 12.07 IFNG IL4 TLR4 TNF
23 12.07 IFNG IL10 IL4 IL5 TNF
24 12.06 FCER2 IL10 IL13 IL4 TNF
25 11.97 FCER2 IL4 IL5 TNF
26 11.96 IFNG IL10 TLR2 TLR4 TNF
27
Show member pathways
11.95 IFNG IL10 TLR2 TLR4 TLR9 TNF
28 11.93 IFNG TLR2 TLR4 TNF
29
Show member pathways
11.92 IFNG IL4 TLR2 TLR4 TLR9
30 11.9 FCER2 TLR2 TLR4 TLR9
31 11.88 IFNG IL13 IL4 IL5
32 11.84 IFNG IL10 TLR9 TNF
33
Show member pathways
11.83 FOXP3 IFNG IL4 IL5 TNF
34 11.78 IFNG IL10 IL13 IL4 IL5 TNF
35 11.77 IL10 TLR4 TNF
36 11.76 FCER2 IL10 IL4 IL5
37 11.75 IL13 IL4 IL5 TNF
38 11.62 TLR2 TLR4 TNF
39 11.62 IFNG TLR2 TLR4 TNF
40 11.57 FCER2 IL10 IL13 IL4 TNF
41 11.49 IFNG IL10 TLR2 TLR4 TLR9 TNF
42
Show member pathways
11.46 FOXP3 IFNG IL10 TNF
43 11.44 IFNG IL10 TLR9 TNF
44 11.42 IL10 TLR4 TNF
45 11.4 FOXP3 IFNG IL10 IL13 IL4 IL5
46 11.39 IFNG IL4 IL5
47 11.34 IFNG IL13 IL4 IL5 TNF
48 11.29 IL10 IL13 IL4 IL5 TNF
49 11.18 IFNG IL10 IL13 IL4 IL5
50 11.04 FOXP3 IL10 IL4 IL5 TLR2 TLR4

GO Terms for Cutaneous Leishmaniasis

Cellular components related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 GPI IFNG IL10 IL13 IL4 IL5
2 external side of plasma membrane GO:0009897 9.46 FCER2 IL13 TLR4 TNF
3 extracellular region GO:0005576 9.28 FCER2 GPI IFNG IL10 IL13 IL4

Biological processes related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.97 IL10 IL13 SLC11A1 TLR2 TLR4
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 TLR2 TLR4 TLR9 TNF
3 response to virus GO:0009615 9.91 FOXP3 IFNG TNF
4 positive regulation of DNA binding transcription factor activity GO:0051091 9.91 IL10 IL5 TNF
5 defense response to Gram-negative bacterium GO:0050829 9.89 SLC11A1 TLR4 TLR9
6 positive regulation of JNK cascade GO:0046330 9.89 TLR4 TLR9 TNF
7 positive regulation of inflammatory response GO:0050729 9.88 TLR2 TLR4 TLR9
8 humoral immune response GO:0006959 9.88 GPI IFNG TNF
9 positive regulation of tumor necrosis factor production GO:0032760 9.87 TLR2 TLR4 TLR9
10 toll-like receptor signaling pathway GO:0002224 9.86 TLR2 TLR4 TLR9
11 positive regulation of interferon-gamma production GO:0032729 9.86 SLC11A1 TLR4 TNF
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IFNG TLR4 TNF
13 negative regulation of tumor necrosis factor production GO:0032720 9.83 FOXP3 IL10 TLR4
14 positive regulation of interleukin-6 production GO:0032755 9.83 TLR2 TLR4 TLR9 TNF
15 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.81 TLR2 TLR4 TLR9
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 TLR2 TLR4 TNF
17 negative regulation of endothelial cell apoptotic process GO:2000352 9.8 IL10 IL13 IL4
18 negative regulation of interferon-gamma production GO:0032689 9.79 FOXP3 IL10 TLR4
19 positive regulation of interferon-beta production GO:0032728 9.79 TLR2 TLR4 TLR9
20 positive regulation of interleukin-10 production GO:0032733 9.78 TLR2 TLR4 TLR9
21 positive regulation of macrophage activation GO:0043032 9.77 IL10 IL13 TLR4
22 positive regulation of interleukin-8 production GO:0032757 9.76 TLR2 TLR4 TLR9 TNF
23 inflammatory response GO:0006954 9.76 IL10 IL13 IL5 SLC11A1 TLR2 TLR4
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 IFNG TNF
25 response to molecule of bacterial origin GO:0002237 9.74 IL10 TLR2 TLR9
26 microglial cell activation GO:0001774 9.73 IL13 TLR2
27 negative regulation of growth of symbiont in host GO:0044130 9.73 IL10 TNF
28 regulation of regulatory T cell differentiation GO:0045589 9.73 FOXP3 IFNG
29 positive regulation of podosome assembly GO:0071803 9.73 IL5 TNF
30 I-kappaB phosphorylation GO:0007252 9.73 TLR2 TLR4 TLR9
31 positive regulation of interleukin-12 production GO:0032735 9.73 IFNG TLR2 TLR4 TLR9
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL10 TNF
33 positive regulation of immunoglobulin secretion GO:0051024 9.72 GPI IL5
34 cellular response to lipoteichoic acid GO:0071223 9.72 TLR2 TLR4
35 macrophage activation GO:0042116 9.72 SLC11A1 TLR4
36 regulation of cytokine secretion GO:0050707 9.72 TLR2 TLR4 TLR9
37 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR4 TNF
38 endothelial cell apoptotic process GO:0072577 9.71 IL10 TNF
39 positive regulation of immunoglobulin production GO:0002639 9.71 IL13 TLR9
40 negative regulation of interleukin-17 production GO:0032700 9.71 FOXP3 IFNG TLR4
41 positive regulation of NF-kappaB import into nucleus GO:0042346 9.71 TLR2 TLR4 TLR9 TNF
42 positive regulation of interferon-beta biosynthetic process GO:0045359 9.7 TLR4 TLR9
43 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 IL10 TNF
44 type 2 immune response GO:0042092 9.7 IL10 IL4
45 negative regulation of interleukin-8 production GO:0032717 9.69 IL10 TLR9
46 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IL10 IL4 TLR4
47 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.68 FCER2 TNF
48 positive regulation of killing of cells of other organism GO:0051712 9.68 FCER2 IFNG
49 regulation of isotype switching GO:0045191 9.68 IL10 IL4
50 positive regulation of interleukin-18 production GO:0032741 9.67 TLR2 TLR9

Molecular functions related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 GPI IL10 IL4 IL5
2 cytokine activity GO:0005125 9.17 GPI IFNG IL10 IL13 IL4 IL5
3 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4

Sources for Cutaneous Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....